Physiometrix submits anaesthesia monitor to FDA:
This article was originally published in Clinica
Executive Summary
Physiometrix has submitted a 510(k) marketing application to the US FDA for its PSA 5000 next generation device for monitoring and managing a patient's level of consciousness while under anaesthesia. The PSA 5000 is more powerful, cost effective and ergonomic than its predecessor, the PSA 4000, said the North Billerica, Massachusetts company. "We believe this next generation technology, with several new features, will further differentiate us from our competition," added John Williams, the firm's president and CEO.